ResearcherColumbia UniversityActive in the last 2 years
Takayuki Tanaka
Matched on OpenAlex author ID A5108113621. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 24
2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 5
- Neoadjuvant Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score-matched Study. Co-author DOI 10.21873/anticanres.18364↗
- Prognostic Impact of Relative Dose Intensity of Adjuvant Chemotherapy With S-1 on Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.15802↗
- Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression. Co-author DOI 10.1136/gutjnl-2019-319912↗
- β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.11.007↗
- Increased expression of PHD3 represses the HIF-1 signaling pathway and contributes to poor neovascularization in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-014-1030-3↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Masaaki Hidaka · 2 shared papers, 2022–2026 · strength 0.43
- Paper Neoadjuvant Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score-matched Study. DOI 10.21873/anticanres.18364↗
- Paper Prognostic Impact of Relative Dose Intensity of Adjuvant Chemotherapy With S-1 on Pancreatic Ductal Adenocarcinoma. DOI 10.21873/anticanres.15802↗
- Takashi Kishi · 1 shared paper, 2026 · strength 0.30
- Tamotsu Kuroki · 2 shared papers, 2015–2022 · strength 0.17
- Paper Prognostic Impact of Relative Dose Intensity of Adjuvant Chemotherapy With S-1 on Pancreatic Ductal Adenocarcinoma. DOI 10.21873/anticanres.15802↗
- Paper Increased expression of PHD3 represses the HIF-1 signaling pathway and contributes to poor neovascularization in pancre… DOI 10.1007/s00535-014-1030-3↗
- Hajime Matsushima · 2 shared papers, 2015–2022 · strength 0.17
- Paper Prognostic Impact of Relative Dose Intensity of Adjuvant Chemotherapy With S-1 on Pancreatic Ductal Adenocarcinoma. DOI 10.21873/anticanres.15802↗
- Paper Increased expression of PHD3 represses the HIF-1 signaling pathway and contributes to poor neovascularization in pancre… DOI 10.1007/s00535-014-1030-3↗
- Susumu Eguchi · 2 shared papers, 2015–2022 · strength 0.17
- Paper Prognostic Impact of Relative Dose Intensity of Adjuvant Chemotherapy With S-1 on Pancreatic Ductal Adenocarcinoma. DOI 10.21873/anticanres.15802↗
- Paper Increased expression of PHD3 represses the HIF-1 signaling pathway and contributes to poor neovascularization in pancre… DOI 10.1007/s00535-014-1030-3↗
- Alina Cornelia Iuga · 2 shared papers, 2018–2021 · strength 0.16
- Marina Macchini · 2 shared papers, 2018–2021 · strength 0.16
- Ryota Takahashi · 2 shared papers, 2018–2021 · strength 0.16
- Bernhard Willibald Renz · 2 shared papers, 2018–2021 · strength 0.16
- Kenneth P. Olive · 2 shared papers, 2018–2021 · strength 0.16
- Christoph Benedikt Westphalen · 2 shared papers, 2018–2021 · strength 0.16
- Timothy Cragin Wang · 2 shared papers, 2018–2021 · strength 0.16
- Hajime Imamura · 1 shared paper, 2022 · strength 0.13
- Ruth Aroon White · 1 shared paper, 2021 · strength 0.11
- Masaki Sunagawa · 1 shared paper, 2021 · strength 0.11
- Tamas A. Gonda · 1 shared paper, 2021 · strength 0.11
- Jeanine M. Genkinger · 1 shared paper, 2021 · strength 0.11
- Riccardo Casadei · 1 shared paper, 2018 · strength 0.06
- Matthias Ilmer · 1 shared paper, 2018 · strength 0.06
- H. Carlo Maurer · 1 shared paper, 2018 · strength 0.06
- Mariacristina Di Marco · 1 shared paper, 2018 · strength 0.06
- Zahra Dantes · 1 shared paper, 2018 · strength 0.06
- Maximilian Reichert · 1 shared paper, 2018 · strength 0.06
- Jens Werner · 1 shared paper, 2018 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.